Ballicules.com

Amphetamine XR suspension

DYANAVEL XR

What it isExtended-release amphetamine suspension (DYANAVEL XR, 2015) that releases norepinephrine, dopamine, and serotonin; ADHD.

Why this oneThe liquid permits fine dose adjustment: 2.5 mg = 4 mg mixed salts, with 8-12 h (Carlat Table 1) of action.

What limits itAppetite loss, insomnia, cardiovascular stimulation, and abuse risk remain those of amphetamine.

FDA-approved for

FDA label

BOXED WARNING High potential for abuse, misuse, and addiction; misuse/abuse of CNS stimulants can result in overdose and death. Assess abuse risk before prescribing and monitor throughout treatment.
FDA dosingPopulationStartTargetMax
Attention Deficit Hyperactivity Disorder (ADHD)Patients 6 years and older2.5 or 5 mg QD in the morningTitrate to clinical response20 mg QD

Titration Increase in increments of 2.5 to 10 mg/day every 4 to 7 days

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Limited data insufficient to determine risk; may cause IUGR and premature delivery; monitor neonates for withdrawal

Lactation Amphetamine present in human milk; breastfeeding not recommended during treatment

⚠ BOXED WARNING

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Amphetamine XR suspension ballicule

Amphetamine XR suspension ballicule: receptor binding, kinetics and half-life diagram

Open Amphetamine XR suspension in the interactive console ↗

Memory aids: mascots and interaction avatars

Amphetamine XR suspension DYANAVEL XR mascot mnemonic cartoon
“Dye Anna’s velvet amp”
Amphetamine XR suspension weak base avatar
weak base

Open Amphetamine XR suspension in the interactive console ↗